Albireo Pharma, Inc.

NasdaqCM:ALBO Stock Report

Market Cap: US$921.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Albireo Pharma Valuation

Is ALBO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALBO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALBO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALBO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALBO?

Other financial metrics that can be useful for relative valuation.

ALBO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue12.3x
Enterprise Value/EBITDA-5.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ALBO's PS Ratio compare to its peers?

The above table shows the PS ratio for ALBO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average17.2x
SLN Silence Therapeutics
35.7x28.4%US$815.7m
KNSA Kiniksa Pharmaceuticals International
5.3x17.8%US$1.7b
ZYME Zymeworks
14.1x8.2%US$886.0m
ADMA ADMA Biologics
13.7x14.8%US$4.5b
ALBO Albireo Pharma
16.1x51.1%US$921.1m

Price-To-Sales vs Peers: ALBO is expensive based on its Price-To-Sales Ratio (16.1x) compared to the peer average (7.9x).

Price to Earnings Ratio vs Industry

How does ALBO's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.4%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.4%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: ALBO is expensive based on its Price-To-Sales Ratio (16.1x) compared to the US Biotechs industry average (11.5x)

Price to Sales Ratio vs Fair Ratio

What is ALBO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALBO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.1x
Fair PS Ratio19x

Price-To-Sales vs Fair Ratio: ALBO is good value based on its Price-To-Sales Ratio (16.1x) compared to the estimated Fair Price-To-Sales Ratio (19x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALBO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Sep ’25n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Aug ’25n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Jul ’25n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Jun ’25n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
May ’25n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Apr ’25n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Mar ’25n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Feb ’25n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Jan ’25n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Dec ’24n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Nov ’24n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Oct ’24n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Sep ’24n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Aug ’24n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Jul ’24n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Jun ’24n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
May ’24n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Apr ’24n/a
US$44.50
0%
6.1%US$48.00US$42.00n/a6
Mar ’24US$44.25
US$44.50
+0.6%
6.1%US$48.00US$42.00n/a6
Feb ’24US$44.70
US$44.50
-0.4%
6.1%US$48.00US$42.00n/a6
Jan ’24US$21.61
US$57.14
+164.4%
13.4%US$68.00US$48.00n/a7
Dec ’23US$22.94
US$57.14
+149.1%
13.4%US$68.00US$48.00n/a7
Nov ’23US$22.58
US$57.43
+154.3%
13.0%US$68.00US$48.00n/a7
Oct ’23US$19.36
US$52.29
+170.1%
14.8%US$68.00US$43.00n/a7
Sep ’23US$17.59
US$52.83
+200.4%
18.1%US$68.00US$40.00n/a6

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y